All In Biotech

Drug Trial Radar · NCT05699239

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 326 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

326

Actual

Start

Feb 8, 2023

Primary completion

Dec 26, 2023

Study completion Dec 26, 2023

Sponsor

Sponsor type
Industry
First posted
Jan 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis

Conditions

  • Hyperphosphatemia Patients on Hemodialysis

Interventions

  • TS-172 10mg bidDrug

    oral administration of TS-172 10 mg bid

  • TS-172 30mg bidDrug

    oral administration of TS-172 30 mg bid

  • TS-172 60mg bidDrug

    oral administration of TS-172 60 mg bid

  • TS-172 20mg tidDrug

    oral administration of TS-172 20 mg tid

  • PlaceboDrug

    oral administration of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in serum concentration of phosphorusTime frame: Week 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taisho Pharmaceutical Co., Ltd selected site

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.